Kansas Board of Pharmacy seeks clearer rules on emergency kits and drug distribution systems for long‑term care

The Joint Committee on Administrative Rules and Regulations reviewed proposed amendments from the Kansas Board of Pharmacy that would split an existing regulation into two clearer parts: one governing emergency kits in long‑term care facilities and one governing drug distribution systems for facilities served by pharmacies.

Bradford DeYoung, an attorney for the Board of Pharmacy, told the committee the board found the prior regulation conflated two separate topics and that splitting the rule will reduce confusion for inspectors and licensees. "68710 will only govern e‑kits or emergency kits in long‑term care facilities," DeYoung said, explaining the kits are statutorily created and "ownership will remain with the pharmacy that provides the consulting services to the long‑term care facility." He described the kits as sealed containers that hold drugs used for sudden, unforeseen conditions such as epinephrine for anaphylaxis or glucagon for severe hypoglycemia.

The board proposes clarifications that require the pharmacy to audit kit contents after use or at least every six months, ensure the kit's labeled expiration date is no later than the earliest expiring drug inside, and prohibit pharmacies from re‑dispensing drugs returned from facilities if the drugs have been removed from their original packaging.

Legislators asked for detail on the definition of "emergency" and whether the kits may include drugs that address severe but non‑life‑threatening events such as acute pain. DeYoung said the regulation does not list a closed set of drugs; instead the pharmacy and its advisory committee select drugs intended "to the prompt treatment of sudden and unforeseen changes in the patient's condition that present an imminent threat to the patient's life or well‑being." He agreed to take committee feedback to the board for further discussion.

Other questions focused on logistics and cost. Senator Tyson asked whether rules had changed in statute to require the regulatory revisions; DeYoung said the changes stem from the board's scheduled five‑year review of regulations and from repeated stakeholder questions and inspection findings indicating the old text was confusing. Representative Sutton and others asked who pays for kit audits and replacements; DeYoung said e‑kits are owned by pharmacies and billing for administered drugs follows normal reimbursement channels, which the board does not regulate.

Senators and representatives also asked whether the proposed changes align with federal guidance, including Drug Enforcement Administration practice for emergency kits; DeYoung said he would bring the committee’s feedback back to the board and inspectors for further consideration.

The committee did not take formal action on the rule at the hearing. Board staff said the substantive duties required of pharmacies and facilities remain largely unchanged; the amendments primarily reorganize and simplify language to reduce compliance confusion.